These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25368431)

  • 21. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
    Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
    Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
    Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
    Front Immunol; 2022; 13():923194. PubMed ID: 35935940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.
    Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; O'Malley MS; Carpenter RL; Long DT; Spruill LS; Romeo MJ; Orr BC; Helke KL; Delaney JR
    Cancer Res Commun; 2024 Sep; 4(9):2525-2538. PubMed ID: 39225558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
    Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
    Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
    Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
    Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
    Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification of 11q13 in ovarian carcinoma.
    Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
    Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.
    Miranda A; Pattnaik S; Hamilton PT; Fuss MA; Kalaria S; Laumont CM; Smazynski J; Mesa M; Banville A; Jiang X; Jenkins R; Cañadas I; Nelson BH
    Sci Adv; 2024 May; 10(20):eadj5428. PubMed ID: 38748789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic Signaling Adaptor Proteins.
    Luo LY; Hahn WC
    J Genet Genomics; 2015 Oct; 42(10):521-529. PubMed ID: 26554907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role and expression of FRS2 and FRS3 in prostate cancer.
    Valencia T; Joseph A; Kachroo N; Darby S; Meakin S; Gnanapragasam VJ
    BMC Cancer; 2011 Nov; 11():484. PubMed ID: 22078327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
    Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth.
    Santhana Kumar K; Brunner C; Schuster M; Kopp LL; Gries A; Yan S; Jurt S; Moehle K; Bruns D; Grotzer M; Zerbe O; Schneider G; Baumgartner M
    Cell Oncol (Dordr); 2023 Apr; 46(2):331-356. PubMed ID: 36495366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
    Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
    Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.